2025 Program

Cambridge VIP's Inaugural

Radiopharmaceuticals Venture, Innovation & Partnering Summit

Connecting Investors, Business Leaders, and Strategics to Accelerate Radiopharmaceutical Innovation

October 1, 2025

Join us for an exclusive gathering of senior-level investors, corporate executives, entrepreneurs, and strategics at the Inaugural Radiopharmaceuticals Venture, Innovation & Partnering Summit, October 1, 2025, in Boston, MA. Connect with future partners and investors at intimate networking sessions; gain strategic insights on funding activities, business development, and innovation strategies in radiopharmaceuticals from industry-led panels; hear candid perspectives from radiopharma thought leaders during dynamic fireside chats; and catch up on innovative technologies presented by emerging companies. Building on the successful launch of the Oncology VIP Summit in 2024, this boutique event is positioned as the premier meeting place for key radiopharmaceuticals stakeholders to foster meaningful connections, acquire valuable strategic insights, and drive innovation and collaboration. The meeting is co-located with the Second Annual Oncology Venture, Innovation & Partnering Summit, September 29-30.

Stay Tuned to Attend the Oncology Venture, Innovation, and Partnering Summit





Wednesday, October 1

    Registration and Morning Coffee

    Organizer's Welcome Remarks

    Co-Chair's Opening Remarks

    Lori Lyons-Williams, President & CEO, Abdera Therapeutics , President & CEO , Abdera Therapeutics

    Igniting the Future of Cancer Care: The Rise of Radioligand Therapy

    Photo of John Wu, PhD, Managing Director & Partner, Boston Consulting Group , Managing Director and Partner , Boston Consulting Group
    John Wu, PhD, Managing Director & Partner, Boston Consulting Group , Managing Director and Partner , Boston Consulting Group

    Radioligand therapy (RLT) unites the precision of targeted therapy with the power of radiation. With blockbuster launches, >60 assets in development, and next-gen innovation in isotopes and targeting, RLT is poised to expand its reach and impact. Yet, scaling will require establishing proof-of-concept in tumors beyond prostate and NETs and overcoming supply chain and manufacturing hurdles. This talk explores the business outlook, opportunities, and challenges shaping the future of RLT.

    Keynote Fireside Chat

    Photo of Geoff Towle, MBA, Therapeutic Area Strategy Head, RLT, Novartis , Therapeutic Area Strategy Head, RLT , Novartis Pharma AG
    Geoff Towle, MBA, Therapeutic Area Strategy Head, RLT, Novartis , Therapeutic Area Strategy Head, RLT , Novartis Pharma AG
    Photo of John Wu, PhD, Managing Director & Partner, Boston Consulting Group , Managing Director and Partner , Boston Consulting Group
    John Wu, PhD, Managing Director & Partner, Boston Consulting Group , Managing Director and Partner , Boston Consulting Group

    Panel Moderator:

    PANEL DISCUSSION:
    Leadership of Targeted Radiopharmaceutical Companies in a Dynamic Landscape

    Jeff Jones, PhD, Managing Director, Equity Research, Oppenheimer & Co., Inc. , Managing Director, Sr. Analyst , Equity Research , Oppenheimer & Co Inc

    Panelists:

    Rachel Humphrey, MD, President and Founding CEO, Normunity , President and Founding CEO , Normunity

    Lori Lyons-Williams, President & CEO, Abdera Therapeutics , President & CEO , Abdera Therapeutics

    Matthew Roden, PhD, President & CEO, Aktis Oncology; Entrepreneur Partner, MPM BioImpact , President & CEO , Aktis Oncology

    Networking Coffee Break

    Networking Coffee Break

    Panel Moderator:

    PANEL DISCUSSION:
    BioPharma Perspective on Radioligand Therapy Development and Partnering

    Matthew Roden, PhD, President & CEO, Aktis Oncology; Entrepreneur Partner, MPM BioImpact , President & CEO , Aktis Oncology

    Panelists:

    Eric Burak, PhD, CTO, Fusion Pharmaceuticals , CTO , Fusion Pharmaceuticals Inc

    Daniel Pryma, MD, Vice President, Global Clinical Development, Eli Lilly and Company , VP Global Clinical Dev , Global Clinical Dev , Eli Lilly & Co

    Eduardo Sarreta, Vice President, Finance & Business Development, RayzeBio, a Bristol Myers Squibb Company , Vice President , Finance & Business Development , RayzeBio

    Geoff Towle, MBA, Therapeutic Area Strategy Head, RLT, Novartis , Therapeutic Area Strategy Head, RLT , Novartis Pharma AG

    Luncheon Discussions

    Co-Chair's Remarks

    Elcin Zan, MD, Chair, Division of Nuclear Medicine, Cleveland Clinic , Chair, Nuclear Medicine , Imaging Institute , Cleveland Clinic

    Panel Moderator:

    PANEL DISCUSSION:
    Investment Outlook in Radiopharmaceuticals and Key Learnings from Early Investment

    Melissa McCracken, PhD, Partner, Nextech Ventures LLC , Partner , Nextech Ventures LLC

    Panelists:

    Jamil M. Beg, Partner, SV Health Investors , Partner , SV Health Investors

    Brian Goodman, PhD, Managing Director, Vida Ventures , Managing Dir , Vida Ventures LLC

    Michael Partsch, MBA, Chief Venture Officer, Wisconsin Alumni Research Foundation , Chief Venture Officer , Wisconsin Alumni Research Foundation WARF

    Laura Tadvalkar, PhD, Managing Director, RA Capital Management , Managing Director , RA Capital Management

    Panel Moderator:

    PANEL DISCUSSION:
    Scaling Up Patient Access to Radiopharmaceuticals and Clinical Trials

    Elcin Zan, MD, Chair, Division of Nuclear Medicine, Cleveland Clinic , Chair, Nuclear Medicine , Imaging Institute , Cleveland Clinic

    Panelists:

    Gwyn Bebb, MD, PhD, Franchise Head, Oncology, Parexel , Franchise Head , Oncology , Parexel Intl

    Munir Ghesani, MD, CMO, United Theranostics , CMO , United Theranostics

    Manoja Lecamwasam, PhD, System Vice President, Intellectual Property and Life Sciences Innovation, CommonSpirit Health , System VP Intellectual Property and Life Sciences Innovation , Life Sciences & Device & Strategic Innovation , CommonSpirit Health

    Daniel Pryma, MD, Vice President, Global Clinical Development, Eli Lilly and Company , VP Global Clinical Dev , Global Clinical Dev , Eli Lilly & Co

    Co-Chair's Closing Remarks

    Elcin Zan, MD, Chair, Division of Nuclear Medicine, Cleveland Clinic , Chair, Nuclear Medicine , Imaging Institute , Cleveland Clinic

    Closing Refreshments

    Arrive early to attend Oncology Venture, Innovation & Partnering Summit

    CONFERENCE CONTENT
    Julia Boguslavsky
    Executive Director, Conferences
    juliab@healthtech.com

     

    PARTNERING & SPONSORSHIP
    Brian Caine
    Specialized Business Development Manager
    (+1) 908-809-0946
    bcaine@healthtech.com